Preferred Label : MEK inhibitor BI 3011441;
NCIt related terms : BENZAMIDE, N-CYCLOPROPYL-3-(5-((2-FLUORO-4-IODOPHENYL)AMINO)-3,4,6,7-TETRAHYDRO-6,8-DIMETHYL-2,4,7-TRIOXOPYRIDO(4,3-D)PYRIMIDIN-1(2H)-YL)-;
NCIt definition : An orally bioavailable, small-molecule, allosteric inhibitor of mitogen-activated
protein kinase kinase (MAP2K; MAPKK; MEK), with potential antineoplastic activity.
Upon oral administration, MEK inhibitor BI 3011441 specifically targets, binds to
and inhibits the catalytic activity of MEK, thereby inhibiting the activation of MEK-dependent
effector proteins including extracellular signal-regulated kinase (ERK) and inhibits
the proliferation of tumor cells in which the RAS/RAF/MEK/ERK signaling pathway is
overactivated. The threonine/tyrosine protein kinase MEK plays a key role in the RAS/RAF/MEK/ERK
signaling pathway, which is frequently upregulated in a variety of tumor cell types
and regulates key cellular activities including cell growth, proliferation, survival,
differentiation and apoptosis.;
UNII : ATQKMH1DYS;
CAS number : 1456713-44-2;
Molecule name : BI-3011441; BI 3011441; LNP3794;
NCI Metathesaurus CUI : CL1662419;
Origin ID : C179649;
UMLS CUI : C5555841;
Semantic type(s)
- concept_is_in_subset
- has_target
